Sinopharm Group Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinopharm Group Co. Ltd.
China's Shrinking Population Poses New Challenge For Pharma
For the first time in 61 years, China has reported its population is shrinking and the new demographic shift is likely to have a far-reaching impact on the pharma sector. Meanwhile, regulators have accelerated the approval of new COVID-19 drugs to relieve acute shortages.
Money, Life And Pursuit Of Paxlovid: Behind China's Mania For Pfizer COVID Drug
From being little known to sought after by millions, Pfizer’s oral antiviral Paxlovid is fast becoming the most pursued medicine in China, amid the largest outbreak of COVID-19 infections the world has yet seen.
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
'COVID Zero' Weakening Immune Systems? Flu Outbreaks Hit China
China reports flu outbreaks as COVID-19 cases decline, suggesting that population immunity may have been affected by the country's strict "COVID Zero" policies. The cost and availability of flu vaccines in the country are other policy factors playing into the situation.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- China National Medical Device Co., Ltd. (CMIC)
- China National Pharmaceutical Industry Co., Ltd. (Sinopharm CNPIC)
- China National Scientific Instruments & Materials Corporation (Sinopharm CSIMC)
- China Sinopharm International Corporation (Sinopharm International)
- Sinopharm A-THINK Pharmaceutical Co., Ltd
- Sinopharm Group Company Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.